Clinica Vitae Sp. z o.o.
Gdansk, Woj. Pomorskie 80-405
0 studies enrolling now · 2 studies all time
What they study most
Atopic Dermatitis
Studies at this site
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)
— Completed
Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.
— Completed